{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:48:50Z","timestamp":1760042930450},"reference-count":23,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Antiretrovirals that reach higher concentrations in cerebrospinal fluid (CSF) are associated with better control of HIV in CSF and possibly better neurocognitive performance. The objective of this study was to determine whether amprenavir (APV) concentrations in CSF are in the therapeutic range. Individuals were selected based on the use of regimens that included fosamprenavir (FPV), a prodrug of APV, and the availability of stored CSF and matched plasma. Total APV was measured in 119 matched CSF-plasma pairs from 75 subjects by high-performance liquid chromatography (HPLC) (plasma) or liquid chromatography tandem mass spectrometry (LC\/MS\/MS) (CSF). Concentrations were compared to the 50% inhibitory concentration (IC\n            <jats:sub>50<\/jats:sub>\n            ) for wild-type HIV (5.6 ng\/ml). Subjects were predominantly middle-aged (median 44 years) white (57%) men (78%) with AIDS (77%). APV was detected in all but 4 CSF specimens, with a median concentration of 24.8 ng\/ml (interquartile range [IQR], 16.2 to 44.0). The median CSF-to-plasma ratio was 0.012 (IQR, 0.008 to 0.018). CSF concentrations correlated with plasma concentrations (rho = 0.61;\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.0001) and with postdose sampling interval (rho = \u22120.29;\n            <jats:italic>P<\/jats:italic>\n            = 0.0019). APV concentrations in CSF exceeded the median IC\n            <jats:sub>50<\/jats:sub>\n            for wild-type HIV in more than 97% of CSF specimens with detectable APV by a median of 4.4-fold (IQR, 2.9 to 7.9). We conclude that administration of fosamprenavir should contribute to control of HIV replication in the central nervous system (CNS) as a component of effective antiretroviral regimens.\n          <\/jats:p>","DOI":"10.1128\/aac.05098-11","type":"journal-article","created":{"date-parts":[[2012,1,31]],"date-time":"2012-01-31T07:59:10Z","timestamp":1327996750000},"page":"1985-1989","update-policy":"http:\/\/dx.doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":12,"title":["Therapeutic Amprenavir Concentrations in Cerebrospinal Fluid"],"prefix":"10.1128","volume":"56","author":[{"given":"David","family":"Croteau","sequence":"first","affiliation":[{"name":"Departments of Neurosciences, University of California, San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Letendre","sequence":"additional","affiliation":[{"name":"Medicine, University of California, San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brookie M.","family":"Best","sequence":"additional","affiliation":[{"name":"Pediatrics, University of California, San Diego, San Diego, California, USA"},{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven S.","family":"Rossi","sequence":"additional","affiliation":[{"name":"Pediatrics, University of California, San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald J.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Departments of Neurosciences, University of California, San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David B.","family":"Clifford","sequence":"additional","affiliation":[{"name":"Washington University, St. Louis, Missouri, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann C.","family":"Collier","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin B.","family":"Gelman","sequence":"additional","affiliation":[{"name":"University of Texas Medical Branch, Galveston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina M.","family":"Marra","sequence":"additional","affiliation":[{"name":"University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"McArthur","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Allen","family":"McCutchan","sequence":"additional","affiliation":[{"name":"Medicine, University of California, San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Morgello","sequence":"additional","affiliation":[{"name":"Mount Sinai School of Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"Simpson","sequence":"additional","affiliation":[{"name":"Mount Sinai School of Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Way","sequence":"additional","affiliation":[{"name":"Psychiatry, University of California, San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Capparelli","sequence":"additional","affiliation":[{"name":"Pediatrics, University of California, San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Igor","family":"Grant","sequence":"additional","affiliation":[{"name":"Psychiatry, University of California, San Diego, San Diego, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"for the CHARTER Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s11095-005-5271-y","article-title":"Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier","volume":"22","author":"Bachmeier CJ","year":"2005","unstructured":"BachmeierCJ SpitzenbergerTJ ElmquistWF MillerDW. 2005. Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. Pharm. Res. 22:1259\u20131268.","journal-title":"Pharm. Res"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328317a702"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000171409.38490.48"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1212\/WNL.0b013e3181ab2b3b","article-title":"Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy","volume":"73","author":"Cysique LA","year":"2009","unstructured":"CysiqueLA. 2009. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 73:342\u2013348.","journal-title":"Neurology"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.4.927"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420503"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archneur.59.6.923","article-title":"Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA","volume":"59","author":"Ellis RJ","year":"2002","unstructured":"EllisRJ. 2002. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch. Neurol. 59:923\u2013928.","journal-title":"Arch. Neurol"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-010-0006-1"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2009.10.001"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2007.31"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2173-2175.2000"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/ana.20198","article-title":"Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders","volume":"56","author":"Letendre SL","year":"2004","unstructured":"LetendreSL. 2004. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann. Neurol. 56:416\u2013423.","journal-title":"Ann. Neurol"},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1086\/523002","article-title":"Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid","volume":"54","author":"Letendre SL","year":"2007","unstructured":"LetendreSL. 2007. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin. Infect. Dis. 54:1511\u20131517.","journal-title":"Clin. Infect. Dis"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1097\/QAD.0b013e32832c4152","article-title":"Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance","volume":"23","author":"Marra CM","year":"2009","unstructured":"MarraCM. 2009. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359\u20131366.","journal-title":"AIDS"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.410420618","article-title":"Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center","volume":"42","author":"Masliah E","year":"1997","unstructured":"MasliahE HeatonRK Marcotte. 1997. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann. Neurol. 42:963\u2013972.","journal-title":"Ann. Neurol"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410420504"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.2.437-443.2004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.12.3663-3668.2001"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1468-1293.2010.00898.x","article-title":"Viral response in stable patients switching to fosamprenavir\/ritonavir monotherapy (the FONT Study)","volume":"12","author":"Saumoy M","year":"2011","unstructured":"SaumoyM. 2011. Viral response in stable patients switching to fosamprenavir\/ritonavir monotherapy (the FONT Study). HIV Med. 12:438\u2013441.","journal-title":"HIV Med"},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1212\/01.WNL.0000145763.68284.15","article-title":"Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia","volume":"63","author":"Sevigny JJ","year":"2004","unstructured":"SevignyJJ. 2004. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 63:2084\u20132090.","journal-title":"Neurology"},{"key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/QAI.0b013e3181af83d6","article-title":"Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders","volume":"52","author":"Tozzi V","year":"2009","unstructured":"TozziV. 2009. Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders. J. Acquir. Immune Defic. Syndr. 52:56\u201363.","journal-title":"J. Acquir. Immune Defic. Syndr"},{"key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1016\/j.antiviral.2008.12.013","article-title":"The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research","volume":"82","author":"Varatharajan L","year":"2009","unstructured":"VaratharajanL ThomasSA. 2009. The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res. 82:A99\u2013A109.","journal-title":"Antiviral Res"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.18.7089"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05098-11","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.05098-11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T22:13:34Z","timestamp":1645481614000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.05098-11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1128\/AAC.05098-11"],"URL":"https:\/\/doi.org\/10.1128\/aac.05098-11","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"type":"print","value":"0066-4804"},{"type":"electronic","value":"1098-6596"}],"subject":[],"published":{"date-parts":[[2012,4]]},"assertion":[{"value":"2011-08-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-01-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}